Infinx vs SamaCare
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Infinx | SamaCare | |
|---|---|---|
| Pricing model | Enterprise contract (custom) · Software plus services, quote-based | Free to providers (funded by payers/pharma) · Pharma funds premium services and data |
| Speed to go live | Standard EHR integration project | Web portal, no IT project required |
| Automation model | Tech-enabled service · AI agents plus expert staff | Software platform · Unified PA portal, AI touchless tier |
| Built for | Mid-size groups, Enterprise systems, Billing companies | Small practices, Mid-size groups |
| Security posture | HITRUST, SOC 2 Type II, HIPAA | SOC 2 Type I, HIPAA |
| Company maturity | 14 yrs (est. 2012) | 8 yrs (est. 2018) |
| Financial backing | $186M reported · Growth (KKR minority stake 2024) | $33M+ · Series B |
| Named customers | None public | None public |
| Published results | No public numbers | No public numbers |
| Documented integrations | 5 listed | 4 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick Infinx if you want prior auth and revenue cycle work handled by a blend of AI and human specialists rather than buying software your staff must run.
- Pick SamaCare if you are a specialty practice buried in medical-benefit prior auths and want one free web portal replacing faxes and payer portals today.
Infinx
AI plus specialists for prior auth and patient access
- Founded
- 2012
- HQ
- San Jose, CA
- Stage
- Growth (KKR minority stake 2024)
- Raised
- $186M reported
What it does
- AI prior authorization determination, submission, and status tracking
- Eligibility verification and benefits checks in one platform
- Patient pay estimates before service
- Certified specialists work exceptions automation cannot resolve
- AR recovery and denial management services
Where it's strong
- The AI-plus-human model delivers completed authorizations, not just software your staff still has to work.
- Deep roots in high-volume prior auth specialties like radiology, labs, and cardiology.
- Trusted by more than 900 provider organizations, with KKR and Norwest backing.
What buyers should weigh
- Part of the value is outsourced labor, so compare its per-transaction economics against pure software options.
- Named customer references are rare in public materials; case studies are anonymized.
- Broad service catalog means implementation scope needs careful definition up front.
Integrations
SamaCare
Prior authorization platform for buy-and-bill specialty drugs
- Founded
- 2018
- HQ
- San Francisco, CA
- Stage
- Series B
- Raised
- $33M+
What it does
- One portal for all medical benefit PA submissions
- AI-assisted form completion and payer requirements
- Status tracking, renewals, and expiration alerts
- Benefit verification and enrollment workflows
- Approval analytics across a 20K-provider network
Where it's strong
- Purpose-built for buy-and-bill drugs, a workflow retail-focused PA tools handle poorly.
- Free for practices because pharma funds it, which removes the budget fight.
- Network data from roughly 20,000 providers improves payer form accuracy and approval odds.
What buyers should weigh
- The pharma-funded model means manufacturers see aggregate data; understand the data terms before signing.
- Scope is medication PA for specialty drugs, not procedures, imaging, or surgical auths.
- Smaller company (Series B) than incumbent networks, so vendor risk is higher than with McKesson or Optum.
Integrations
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.